ESR1 and breast cancer: Since patients with ER or PR negative, HER-2 positive, basal-like or triple-negative status generally display therapy insensitivity and inferior prognosis, our results suggested that lower expression of BIRC5 may predict a satisfied clinical outcome of breast cancer.